Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
CellaVision AB is a Sweden-based medical technology company specializing in digital hematology microscopy solutions. Established in 1994 and headquartered in Lund, Sweden, it develops and sells advanced analyzers, staining reagents, smearing and staining devices, and software to automate cell classification and analysis in laboratories worldwide. With over 250 employees, market support offices in 12 to 16 markets, and a presence in more than 40 countries, CellaVision manufactures reagents in-house in Martillac, France, while outsourcing analyzer production in Sweden. The company leverages deep learning and artificial intelligence to enhance laboratory workflows, minimize human error, and improve diagnostic certainty for human and animal blood and body fluid samples. Its mission focuses on advancing laboratory efficiency and healthcare through intelligent microscopy, with notable achievements including over 30 years of experience and more than 8,000 units sold. CellaVision plays a pivotal role in the medical diagnostic equipment sector by standardizing processes, fostering collaboration, and elevating global hematology standards.
kr 12.72
+kr 0.50 (+4.09%)
EOD Jun 23, 2026 · Twelve Data
Margins and capital returns are both well above average: 26.62% operating margin, ROIC at 18.14%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 4.9%, steady but not accelerating.
Even for strong businesses, today's 2x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
2.3x earnings, 2.5x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 731M
▲ +4.9% YoY
Net Income (TTM)
kr 134M
▲ +8.8% YoY
Op. Margin
23.74%
▲ +2.1pp YoY
ROIC
18.14%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 120M
▼ -5.3% YoY
Op. Cash Flow (TTM)
kr 193M
▲ +4.2% YoY
Net Debt
-kr 163M
Net Cash Position
Cash & Equiv.
kr 188M
3Y CAGR: +5.9%
3Y CAGR: +19.0%
Continue Research
At a P/E of 2.3 and a price-to-free-cash-flow of 2.5, CellaVision AB (CEVI.XSTO) trades below a two-stage DCF intrinsic value of about SEK 146.51 per share, so at SEK 12.72 the stock looks undervalued (1,051.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, CellaVision AB scores 77/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 19.7%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 146.51 per share for CEVI.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 109.88. At today's SEK 12.72, that puts the stock about 1,051.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
CellaVision AB scores 77 out of 100 on Intrinsiqq's quality score, passing 6 of 8 checks, which makes it a solid business on these measures. Recent fundamentals include a 23.7% operating margin and a 18.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, CellaVision AB pays a regular dividend of about SEK 2.50 per share per year (typically in quarterly installments), a yield of roughly 19.7% at the current price. That is a payout ratio of about 44.5% of earnings, so the dividend is well covered. CellaVision AB has grown the dividend at roughly 35.1% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For CEVI.XSTO's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. CEVI.XSTO currently trades below its estimated intrinsic value and scores 77/100 on quality (solid). It also yields about 19.7%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.